Search results
Atossa ( Old Persian: Utauθa, or Old Iranian: Hutauθa; 550–475 BC) was an Achaemenid empress. She was the daughter of Cyrus the Great, and the wife of Darius the Great .
Atossa Therapeutics develops innovative medicines for breast cancer prevention and treatment, using a proprietary (Z)-endoxifen compound. Learn about their lead program, the EVANGELINE study, and their mission to transform the breast cancer paradigm.
Find the latest Atossa Therapeutics, Inc. (ATOS) stock quote, history, news and other vital information to help you with your stock trading and investing.
Feb 22, 2024 · Atossa Therapeutics is developing (Z)-endoxifen, a Selective Estrogen Receptor Modulator (SERM), for various breast cancer indications. The company announced the first patient dosing of (Z)-endoxifen in a Phase 2 study for ductal carcinoma in situ (DCIS), a pre-invasive form of breast cancer.
Mar 19, 2024 · A U.S. breast cancer patient received (Z)-endoxifen, a tamoxifen metabolite, under an FDA-approved expanded access program for five years and remained cancer-free. (Z)-endoxifen is a selective estrogen receptor modulator (SERM) that may have advantages over tamoxifen and aromatase inhibitors.
Oct 15, 2023 · Queen Atossa was a force to reckon with in the Achaemenid Empire. As strategic leader, and mother to a future emperor, her impact echoes through time. The famed Achaemenid Empire was an ancient Iranian empire that was founded by the renowned Cyrus the Great in 550 BC.
Oct 24, 2022 · SEATTLE, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology with a current focus on breast cancer, announced today that the U.S. Food and Drug Administration (FDA) has lifted the ...
